<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: businesses license rights", fill: "#ff2800"},
{source: "1: businesses license rights", target: "1: technologies", fill: "#ff2800"},
{source: "1: technologies", target: "1: spinoff businesses which could", fill: "#ff2800"},
{source: "1: spinoff businesses which could", target: "1: significant expenses", fill: "#ff2800"},
{source: "1: significant expenses", target: "1: could negatively affect", fill: "#ff2800"},
{source: "1: could negatively affect", target: "1: profitability", fill: "#ff2800"},
{source: "1: businesses license rights", target: "2: Abbott ", fill: "#e9d66b"},
{source: "2: Abbott ", target: "2: acquisitions", fill: "#e9d66b"},
{source: "2: acquisitions", target: "2: complementary businesses", fill: "#e9d66b"},
{source: "2: complementary businesses", target: "2: technology licensing arrangements", fill: "#e9d66b"},
{source: "2: technology licensing arrangements", target: "2: strategic alliances", fill: "#e9d66b"},
{source: "2: strategic alliances", target: "2: product offerings", fill: "#e9d66b"},
{source: "2: product offerings", target: "2: geographic presence as", fill: "#e9d66b"},
{source: "2: Abbott ", target: "4: Other ", fill: "#987654"},
{source: "4: Other ", target: "4: compete with", fill: "#987654"},
{source: "4: compete with", target: "4: opportunities", fill: "#987654"},
{source: "4: Other ", target: "6: integrate acquisitions successfully", fill: "#b8860b"},
{source: "6: integrate acquisitions successfully", target: "6: could incur", fill: "#b8860b"},
{source: "6: could incur", target: "6: significant debt", fill: "#b8860b"},
{source: "6: significant debt", target: "6: contingent liabilities", fill: "#b8860b"},
{source: "6: integrate acquisitions successfully", target: "14: businesses rely on patent", fill: "#2f847c"},
{source: "14: businesses rely on patent", target: "14: intellectual", fill: "#2f847c"},
{source: "14: businesses rely on patent", target: "19: Competitors ", fill: "#a3c1ad"},
{source: "19: Competitors ", target: "19: intellectual property may prevent", fill: "#a3c1ad"},
{source: "19: intellectual property may prevent", target: "19: from selling", fill: "#a3c1ad"},
{source: "19: from selling", target: "19: future profitability", fill: "#a3c1ad"},
{source: "19: future profitability", target: "19: financial condition", fill: "#a3c1ad"},
{source: "19: Competitors ", target: "25: intellectual property infringement could", fill: "#8a2be2"},
{source: "25: intellectual property infringement could", target: "25: significant", fill: "#8a2be2"},
{source: "25: significant", target: "25: injunction preventing", fill: "#8a2be2"},
{source: "25: injunction preventing", target: "25: manufacture sale", fill: "#8a2be2"},
{source: "25: manufacture sale", target: "25: or an Abbott ", fill: "#8a2be2"},
{source: "25: intellectual property infringement could", target: "29: efforts by", fill: "#bfff00"},
{source: "29: efforts by", target: "29: government", fill: "#bfff00"},
{source: "29: government", target: "29: private organizations", fill: "#bfff00"},
{source: "29: private organizations", target: "29: Regulation ", fill: "#bfff00"},
{source: "29: efforts by", target: "33: numerous governmental regulations", fill: "#fc6c85"},
{source: "33: numerous governmental regulations", target: "33: regulations", fill: "#fc6c85"},
{source: "33: regulations", target: "33: comply with", fill: "#fc6c85"},
{source: "33: comply with", target: "33: compliant products", fill: "#fc6c85"},
{source: "33: numerous governmental regulations", target: "37: adverse amendment", fill: "#8c92ac"},
{source: "37: adverse amendment", target: "37: authority necessary", fill: "#8c92ac"},
{source: "37: authority necessary", target: "37: manufacture", fill: "#8c92ac"},
{source: "37: manufacture", target: "37: additional", fill: "#8c92ac"},
{source: "37: additional", target: "37: different regulatory", fill: "#8c92ac"},
{source: "37: different regulatory", target: "37: requirements such as", fill: "#8c92ac"},
{source: "37: requirements such as", target: "37: affecting labeling", fill: "#8c92ac"},
{source: "37: adverse amendment", target: "START_HERE", fill: "#8c92ac"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Return_on_equity">Return on equity</a></td>
      <td>The return on equity (ROE) is a measure of the profitability of a business in relation to the equity. Because shareholder's equity can be calculated by taking all assets and subtracting all liabilities, ROE can also be thought of as a return on assets minus liabilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abbott_Laboratories">Abbott Laboratories</a></td>
      <td>Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tony_Abbott">Tony Abbott</a></td>
      <td>Anthony John Abbott  (; born 4 November 1957) is a former Australian politician. He served as the 28th prime minister of Australia from 2013 to 2015, holding office as the leader of the Liberal Party.Abbott was born in London, England, to an Australian mother and a British father, and moved to Sydney at the age of two.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Greg_Abbott">Greg Abbott</a></td>
      <td>Gregory Wayne Abbott (born November 13, 1957) is an American politician, attorney, and former jurist who has served as the 48th governor of Texas since 2015. A member of the Republican Party, he served as the 50th attorney general of Texas from 2002 to 2015 and as a member of the Texas Supreme Court from 1996 to 2001.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dimebag_Darrell">Dimebag Darrell</a></td>
      <td>Darrell Lance Abbott (August 20, 1966 – December 8, 2004), best known by his stage name Dimebag Darrell, was an American musician. He was the guitarist of the heavy metal bands Pantera and Damageplan, both of which he co-founded alongside his brother Vinnie Paul.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Christopher_Abbott">Christopher Abbott</a></td>
      <td>Christopher Jacob Abbott (born February 1, 1986) is an American actor. Abbott made his feature film debut in Martha Marcy May Marlene (2011).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abbott_Elementary">Abbott Elementary</a></td>
      <td>Abbott Elementary is an American mockumentary sitcom television series created by Quinta Brunson for ABC. It stars Brunson as a second grade teacher at Abbott Elementary, a fictional Black school in Philadelphia. Tyler James Williams, Janelle James, Lisa Ann Walter, Chris Perfetti, and Sheryl Lee Ralph also star.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vehicle_emission_standard">Vehicle emission standard</a></td>
      <td>Emission standards  are the legal requirements governing air pollutants released into the atmosphere. Emission standards set quantitative limits on the permissible amount of specific air pollutants that may be released from specific sources over specific timeframes.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ABBOTT LABORATORIES      ITEM 1A    RISK FACTORS          Abbott may acquire other <font color="blue">businesses</font>, license rights to <font color="blue">technologies</font> or     products, form alliances, or dispose of or spin-off <font color="blue">businesses</font>, which could     cause  it  to  incur  <font color="blue"><font color="blue">significant</font> expenses</font> and <font color="blue">could negatively affect</font>     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Abbott  </font>may  pursue  <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">complementary <font color="blue">businesses</font></font>,     <font color="blue">technology licensing arrangements</font>, and <font color="blue"><font color="blue">strategic alliance</font>s</font> to expand its     <font color="blue">product offerings</font> and <font color="blue">geographic presence as</font> part of its business strategy</td>
    </tr>
    <tr>
      <td><font color="blue">Abbott  </font>may  not  complete these <font color="blue">transactions</font> in a <font color="blue">timely manner</font>, on a     cost-effective basis, or at all, and may not realize the expected benefits     of  any <font color="blue">acquisition</font>, license arrangement, or <font color="blue">strategic alliance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font>companies  may  <font color="blue">compete with</font> Abbott for these strategic <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Further,  even  if Abbott is successful in making the <font color="blue">acquisition</font>, the     products and <font color="blue">technologies</font> that are acquired may not be successful or may     require <font color="blue"><font color="blue">significant</font>ly greater resources</font> and <font color="blue"><font color="blue">investments</font> than originally</font>     anticipated</td>
    </tr>
    <tr>
      <td>Abbott may not be able to integrate <font color="blue"><font color="blue">acquisition</font>s</font> <font color="blue">successfully</font>     into its existing business and <font color="blue">could incur</font> or assume <font color="blue"><font color="blue">significant</font> debt</font> and     unknown or <font color="blue">contingent liabilities</font></td>
    </tr>
    <tr>
      <td>Abbott <font color="blue">could also</font> experience negative     <font color="blue">effects on</font> its reported results of <font color="blue">operations</font> from <font color="blue">acquisition</font>-related     charges, amortization of expenses related to <font color="blue">intangibles</font> and charges for     <font color="blue">impairment</font>  of  long-term  assets</td>
    </tr>
    <tr>
      <td>These  effects, individually or in     <font color="blue">combination</font>, could cause a <font color="blue">deterioration</font> of Abbottapstas credit rating and     result in <font color="blue">increased borrowing costs</font> and <font color="blue">interest expense</font></td>
    </tr>
    <tr>
      <td>Abbott could     experience   <font color="blue">difficulties</font>   in  <font color="blue">integrating</font>  <font color="blue">geographically</font>  separated     <font color="blue">organizations</font>,  systems  and  <font color="blue">facilities</font>,  and  <font color="blue">personnel with diverse</font>     <font color="blue">backgrounds</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integration </font>of an acquired business also may require <font color="blue">management</font>     resources that <font color="blue">otherwise would</font> be available for <font color="blue">ongoing <font color="blue">development</font></font> of     Abbottapstas existing business</td>
    </tr>
    <tr>
      <td>Abbott <font color="blue">may also dispose</font> of or spin-off some of its <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Abbott may not complete these <font color="blue">transactions</font> in a <font color="blue">timely manner</font>, or at all,     and may not realize their expected benefits</td>
    </tr>
    <tr>
      <td>9       _________________________________________________________________       The expiration of <font color="blue">patent protection</font> and <font color="blue">licenses may affect</font> Abbottapstas future     revenues and operating income</td>
    </tr>
    <tr>
      <td>Many of Abbottapstas <font color="blue">businesses</font> rely on patent and trademark and other     <font color="blue">intellectual</font>  property  protection</td>
    </tr>
    <tr>
      <td>Although most of the <font color="blue">challenges</font> to     Abbottapstas <font color="blue">intellectual</font> property have come from other <font color="blue">businesses</font>, <font color="blue">government</font>s     may also challenge <font color="blue">intellectual</font> property protections</td>
    </tr>
    <tr>
      <td>To the extent Abbottapstas     <font color="blue">intellectual</font>  property  is  <font color="blue">successfully</font>  challenged,  invalidated, or     <font color="blue">circumvented</font>  or  to  the  extent  it does not allow Abbott to compete     <font color="blue">effectively</font>, Abbottapstas business will suffer</td>
    </tr>
    <tr>
      <td>To the extent that countries do     not enforce Abbottapstas <font color="blue">intellectual</font> property rights or require <font color="blue">compulsory</font>     licensing  of  its <font color="blue">intellectual</font> property, Abbottapstas <font color="blue">future revenues</font> and     operating <font color="blue">income will</font> be reduced</td>
    </tr>
    <tr>
      <td>Abbottapstas <font color="blue">principal patents</font> and <font color="blue">trademarks</font> are described in greater     detail in the sections captioned,  &amp;quote Patents, Trademarks, and Licenses &amp;quote  and      &amp;quote Financial Review, &amp;quote  and <font color="blue">litigation</font> regarding these patents is described in     the section captioned  &amp;quote <font color="blue">Legal Proceedings </font>&amp;quote</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>&amp;apos  <font color="blue">intellectual</font> property may prevent Abbott <font color="blue">from selling</font> its     products or have a material adverse effect on Abbottapstas future <font color="blue">profitability</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may claim that an Abbott <font color="blue">product infringes upon</font> their     <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>A successful claim of patent or other <font color="blue">intellectual</font>     property  <font color="blue">infringement</font>  against Abbott <font color="blue">could <font color="blue">adversely affect</font></font> Abbottapstas     <font color="blue">profitability</font> or <font color="blue">financial condition</font>, in some <font color="blue">cases materially</font></td>
    </tr>
    <tr>
      <td><font color="blue">Abbott  </font>   <font color="blue">cannot assure</font> that it does not, in fact, infringe upon otherapstas <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td><font color="blue">Resolving </font>an <font color="blue">intellectual</font> property <font color="blue">infringement</font> claim can be     costly and time consuming and may require Abbott to enter into royalty or     license <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>If this should be <font color="blue">necessary</font>, Abbott <font color="blue">cannot guarantee</font>     that  it  would  be  able  to  obtain royalty or license <font color="blue">agreements</font> on     <font color="blue">commercially</font>  reasonable  terms</td>
    </tr>
    <tr>
      <td>A successful claim of patent or other     <font color="blue">intellectual</font> property <font color="blue">infringement</font> could subject Abbott to <font color="blue">significant</font>     damages or an <font color="blue">injunction preventing</font> the <font color="blue">manufacture</font>, sale or use of affected     Abbott products</td>
    </tr>
    <tr>
      <td>Any of these events could have a material adverse effect on     Abbottapstas <font color="blue">profitability</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">the <font color="blue">United States </font></font></font>and other countries, access to and the cost of     <font color="blue">human <font color="blue">health care products</font> continues</font> to be subject to <font color="blue">downward pressure on</font>     prices</td>
    </tr>
    <tr>
      <td>Cost-<font color="blue">containment</font> <font color="blue">efforts by</font> the <font color="blue">government</font> and private <font color="blue">organizations</font>     are described in greater detail in the section captioned  &amp;quote <font color="blue">Regulation </font>&amp;quote</td>
    </tr>
    <tr>
      <td>In <font color="blue">markets outside</font> the United States, Abbottapstas <font color="blue">businesses</font> have     experienced <font color="blue">downward pressure on</font> product pricing</td>
    </tr>
    <tr>
      <td>Many countries, directly     or indirectly, through <font color="blue">limitations on</font> <font color="blue">reimbursement</font> or <font color="blue">availability</font>, control     the <font color="blue">selling price</font> of <font color="blue">most <font color="blue">health care products</font></font></td>
    </tr>
    <tr>
      <td>To the extent these cost     <font color="blue">containment</font> efforts are not offset by greater patient access to healthcare     or other factors, Abbottapstas <font color="blue">future revenues</font> and operating <font color="blue">income will</font> be     reduced</td>
    </tr>
    <tr>
      <td>Abbott is subject to numerous <font color="blue">government</font>al <font color="blue">regulations</font> and it can be costly     to <font color="blue">comply with</font> these <font color="blue">regulations</font> and to develop <font color="blue">compliant products</font> and     processes</td>
    </tr>
    <tr>
      <td>Abbottapstas products are subject to <font color="blue">rigorous regulation by</font> the Federal     Food and Drug Administration, and numerous other national, <font color="blue">supranational</font>,     federal and state <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>     to market a drug or medical device, <font color="blue">particularly from</font> the FDA and certain     <font color="blue">government</font>al  <font color="blue">authorities</font> outside the United States, can be costly and     time-consuming, and <font color="blue">approvals might</font> not be granted for <font color="blue"><font color="blue">future products</font> on</font> a     timely  basis,  if  at  all</td>
    </tr>
    <tr>
      <td><font color="blue">Regulation </font>is not static</td>
    </tr>
    <tr>
      <td>The suspension,     revocation, or <font color="blue">adverse amendment</font> of the authority <font color="blue">necessary</font> for <font color="blue">manufacture</font>,     marketing, or sale, and the imposition of <font color="blue">additional</font> or <font color="blue">different <font color="blue">regulatory</font></font>     <font color="blue">requirements</font>, such as those <font color="blue"><font color="blue">affecting</font> labeling</font> can also occur</td>
    </tr>
    <tr>
      <td>Delays in the     receipt of, or failure to obtain approvals for, <font color="blue"><font color="blue">future products</font> could</font> result     in <font color="blue">delayed realization</font> of <font color="blue">product revenues</font> and in substantial <font color="blue">additional</font>     costs</td>
    </tr>
    <tr>
      <td>In addition, no assurance can be given that Abbott will remain in     compliance  <font color="blue">with applicable</font> FDA and other <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font> once</font>     clearance or approval has been obtained for a product</td>
    </tr>
    <tr>
      <td><font color="blue">These                                         </font>10       _________________________________________________________________       <font color="blue">requirements</font>   include,  among  other  things,  <font color="blue">regulations</font>  regarding     <font color="blue">manufacturing</font> practices, product labeling and <font color="blue">advertising</font> and <font color="blue">postmarketing</font>     reporting,  including  adverse  event  reports and <font color="blue">field alerts due</font> to     <font color="blue"><font color="blue">manufacturing</font> quality concerns</font></td>
    </tr>
    <tr>
      <td>Many of Abbottapstas <font color="blue">facilities</font> and procedures     and those of Abbottapstas suppliers are subject to <font color="blue">ongoing regulation</font>, including     periodic  inspection  by the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>For     example, developers and <font color="blue">manufacture</font>rs of <font color="blue">health care products</font>, including     pharmaceutical products, medical devices, and <font color="blue">nutritional products must</font>     <font color="blue">comply with</font> detailed <font color="blue">regulations</font> governing current good <font color="blue">manufacturing</font>,     <font color="blue">laboratory</font>  and <font color="blue"><font color="blue">clinical practice</font>s</font>, including <font color="blue">requirements</font> relating to     <font color="blue">quality control</font> and <font color="blue">quality assurance</font></td>
    </tr>
    <tr>
      <td>Abbott <font color="blue">must incur expense</font> and spend     time and effort to <font color="blue">ensure <font color="blue">compliance with</font></font> these complex <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In the     past, Abbottapstas business has received notices alleging violations of these     <font color="blue">regulations</font>, and Abbott has <font color="blue">modified practices</font> in response to these notices</td>
    </tr>
    <tr>
      <td>Abbottapstas <font color="blue">manufacturing</font> <font color="blue">facilities</font> and those of Abbottapstas suppliers     could be subject to <font color="blue">significant</font> adverse <font color="blue">regulatory</font> actions in the future</td>
    </tr>
    <tr>
      <td>These <font color="blue">possible <font color="blue">regulatory</font> <font color="blue">actions could</font></font> include warning letters, fines,     damages,  <font color="blue">injunctions</font>,  civil penalties, recalls, seizures of Abbottapstas     products and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">actions could</font> result in, among     other things, substantial <font color="blue">modifications</font> to Abbottapstas business practices and     <font color="blue">operations</font>; refunds, recalls or seizures of Abbottapstas products; a total or     <font color="blue">partial shutdown</font> of production in one or more of Abbottapstas <font color="blue">facilities</font> while     <font color="blue">Abbott  </font>remedies the alleged violation; the <font color="blue">inability</font> to obtain future     pre-market  <font color="blue">clearances</font> or approvals; and <font color="blue">withdrawals</font> or <font color="blue">suspensions</font> of     <font color="blue">current products from</font> the market</td>
    </tr>
    <tr>
      <td>Any of these events, in <font color="blue">combination</font> or     alone, could disrupt Abbottapstas business and have a material adverse effect on     Abbottapstas revenues, <font color="blue">profitability</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Laws and <font color="blue">regulations</font> <font color="blue">affecting</font> <font color="blue">government</font> benefit programs could impose new     <font color="blue">obligations</font> on Abbott, require Abbott to change its business practices, and     restrict its <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>Abbottapstas industry is also subject to <font color="blue">various federal</font> and state laws     pertaining to <font color="blue">government</font> benefit program <font color="blue">reimbursement</font>, price reporting and     regulation, and <font color="blue">health care fraud</font> and abuse, including anti-kickback and     false claims laws, the Medicaid Rebate Statute, the Veterans Health Care Act     and individual state laws relating to pricing</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of these laws may     be  punishable  by criminal and/or civil sanctions, including, in some     instances, substantial fines, <font color="blue">imprisonment</font> and exclusion from <font color="blue">participation</font>     in federal and state health care programs, including Medicare, Medicaid, and     <font color="blue">Veterans Administration </font><font color="blue">health programs</font></td>
    </tr>
    <tr>
      <td>These laws and <font color="blue">regulations</font> are     broad in scope and they are subject to evolving <font color="blue">interpretations</font>, which could     require Abbott to incur substantial costs associated with compliance or to     alter  one  or  more of its sales or <font color="blue">marketing practices</font></td>
    </tr>
    <tr>
      <td>In addition,     violations of these laws, or <font color="blue">allegations</font> of such violations, could disrupt     Abbottapstas  business and result in a material adverse effect on Abbottapstas     revenues, <font color="blue">profitability</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Abbott </font>does not <font color="blue">introduce <font color="blue">new products</font></font> in a <font color="blue">timely manner</font>, Abbottapstas     <font color="blue"><font color="blue">products may</font> become obsolete over</font> time, <font color="blue">customers may</font> not buy Abbottapstas     products, and Abbottapstas revenue and <font color="blue">profitability</font> may decline</td>
    </tr>
    <tr>
      <td>Demand for Abbottapstas <font color="blue">products may</font> change in ways Abbott does not     anticipate</td>
    </tr>
    <tr>
      <td>This could occur, for example, due to changing customer needs,     the <font color="blue"><font color="blue">introduction</font> by others</font> of <font color="blue">new products</font> and <font color="blue">technologies</font>, or changing     <font color="blue">industry standards</font></td>
    </tr>
    <tr>
      <td>Without the timely <font color="blue">introduction</font> of <font color="blue">new products</font> and     <font color="blue">enhancements</font>, Abbottapstas <font color="blue"><font color="blue">products may</font> become obsolete over</font> time, causing     Abbottapstas revenue and operating results to suffer</td>
    </tr>
    <tr>
      <td>Even if Abbott succeeds in     creating  new  product  <font color="blue">candidates</font>,  these  <font color="blue">candidates</font>  may not become     <font color="blue">commercially</font> successful products</td>
    </tr>
    <tr>
      <td>The success of Abbottapstas <font color="blue">new products</font> will depend on a variety of     factors, including Abbottapstas ability to:          •                 properly anticipate and <font color="blue">satisfy customer</font> needs;          •                 innovate, develop, and <font color="blue">manufacture</font> <font color="blue">new products</font> in an economical                 and <font color="blue">timely manner</font>;          •                 differentiate Abbottapstas offerings from <font color="blue">competitors</font> &amp;apos  offerings;          •                 achieve positive <font color="blue">clinical outcomes</font> for <font color="blue">new products</font>;                                         11       _________________________________________________________________       •            meet  safety  <font color="blue">requirements</font> and other <font color="blue">regulatory</font> <font color="blue">requirements</font> of            <font color="blue">government</font> agencies;     •            <font color="blue">avoid infringing</font> the <font color="blue">proprietary rights</font> of <font color="blue">third parties</font>; and     •            establish and maintain its <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td>Even if Abbott <font color="blue">successfully</font> develops <font color="blue">new products</font> or <font color="blue">enhancements</font> or     new  <font color="blue">generations</font>  of Abbottapstas <font color="blue">existing products</font>, these <font color="blue">new products</font> or     <font color="blue">enhancements</font> or new <font color="blue">generations</font> of Abbottapstas existing <font color="blue">products may</font> be quickly     rendered <font color="blue">obsolete by</font> changing <font color="blue">customer preferences</font> or the <font color="blue">introduction</font> by     Abbottapstas <font color="blue">competitors</font> of products embodying new <font color="blue">technologies</font> or features</td>
    </tr>
    <tr>
      <td>Finally, <font color="blue">innovations may</font> not be <font color="blue">accepted quickly</font> in the marketplace because     of, among other things, entrenched patterns of <font color="blue">clinical practice</font>, the need     for <font color="blue"><font color="blue">regulatory</font> clearance</font>, and uncertainty over third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font> of many of Abbottapstas products is a <font color="blue">highly exacting</font> and     <font color="blue">complex process</font>, and if Abbott or one of its suppliers <font color="blue">encounters</font> problems     <font color="blue">manufacturing</font> products, Abbottapstas business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of many of Abbottapstas products is a <font color="blue">highly exacting</font>     and <font color="blue">complex process</font>, due in part to strict <font color="blue">regulatory</font> <font color="blue">requirements</font>, which     govern their <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>Problems may arise during <font color="blue">manufacturing</font> for a     variety of reasons, including equipment malfunction, failure to follow     <font color="blue">specific protocols</font> and procedures, problems with raw materials, natural     <font color="blue">disasters</font> and <font color="blue">environmental factors</font></td>
    </tr>
    <tr>
      <td>If problems arise during the production     of a batch of product, that batch of <font color="blue">product may</font> have to be discarded</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could, among other things, lead to increased costs, lost revenue, damage to     <font color="blue">customer relations</font>, time and <font color="blue">expense spent investigating</font> the cause and,     <font color="blue">depending on</font> the cause, similar <font color="blue">losses with respect</font> to other batches or     products</td>
    </tr>
    <tr>
      <td>If problems are not discovered before the product is released to     the market, recall and <font color="blue"><font color="blue">product <font color="blue">liability</font></font> costs may also</font> be incurred</td>
    </tr>
    <tr>
      <td>To the     extent Abbott or one of its suppliers experiences <font color="blue">significant</font> <font color="blue">manufacturing</font>     problems, this could have a material adverse effect on Abbottapstas revenues and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">international</font> nature of Abbottapstas business subjects it to <font color="blue">additional</font>     business risks that may cause its revenue and <font color="blue">profitability</font> to decline</td>
    </tr>
    <tr>
      <td>Abbottapstas business is subject to <font color="blue">risks associated with</font> doing business     <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>Sales outside of <font color="blue">the <font color="blue">United States </font></font>make up more than 40prca of     Abbottapstas net sales</td>
    </tr>
    <tr>
      <td>The <font color="blue">risks associated with</font> Abbottapstas <font color="blue">operations</font> outside     <font color="blue">the <font color="blue">United States </font></font>include:          •                 changes in <font color="blue">foreign medical <font color="blue">reimbursement</font> policies</font> and programs;          •                 multiple foreign <font color="blue">regulatory</font> <font color="blue">requirements</font> that are subject to                 change and that <font color="blue">could restrict</font> Abbottapstas ability to <font color="blue">manufacture</font>                 and sell its products;          •                 <font color="blue">differing local product preferences</font> and product <font color="blue">requirements</font>;          •                 <font color="blue">fluctuations</font> in <font color="blue">foreign currency exchange rates</font> and in interest                 rates;          •                 trade  protection  measures and import or <font color="blue">export licensing</font>                 <font color="blue">requirements</font>;          •                 <font color="blue">difficulty</font> in establishing, staffing, and <font color="blue">managing foreign</font>                 <font color="blue">operations</font>;          •                 differing labor <font color="blue">regulations</font>;          •                 <font color="blue">potentially</font>  negative  <font color="blue">consequences</font>  from  changes  in  or                 <font color="blue">interpretations</font> of tax laws;          •                 political and <font color="blue">economic <font color="blue">instability</font></font>;          •                 inflation, recession, interest rate <font color="blue">fluctuations</font>, and actual or                 anticipated military or <font color="blue">political conflicts</font>; and          •                 diminished  protection  of  <font color="blue">intellectual</font>  property in some                 countries</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________               These risks may, individually or in the aggregate, have a material     adverse effect on Abbottapstas revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">safety issues could</font> arise for Abbottapstas products, which could     have a material adverse effect on Abbottapstas revenues and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>All <font color="blue">health care products</font>, including pharmaceutical products, medical     products,  and <font color="blue">nutritionals</font>, receive <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">based on</font> data</font>     obtained  in <font color="blue">controlled clinical trials</font> of limited duration</td>
    </tr>
    <tr>
      <td><font color="blue">Following     </font><font color="blue"><font color="blue">regulatory</font> approval</font>, these <font color="blue">products will</font> be <font color="blue">used over longer periods</font> of time     in many patients</td>
    </tr>
    <tr>
      <td><font color="blue">Investigators </font>may also conduct <font color="blue">additional</font>, and perhaps     more extensive, studies or studies for <font color="blue">different indications</font></td>
    </tr>
    <tr>
      <td>If new safety     issues are reported, Abbott may be required to amend the <font color="blue">conditions</font> of use     for a product</td>
    </tr>
    <tr>
      <td>For example, Abbott may be required to provide <font color="blue">additional</font>     <font color="blue">warnings on</font> a productapstas label or narrow its approved indication, either of     <font color="blue">which could reduce</font> the productapstas market acceptance</td>
    </tr>
    <tr>
      <td>If <font color="blue">serious safety issues</font>     with an Abbott product arise, sales of the <font color="blue">product could</font> be <font color="blue">halted by</font> <font color="blue">Abbott  </font>   or by <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In addition, in the ordinary course of business, Abbott is the     subject of <font color="blue">product <font color="blue">liability</font></font> claims and lawsuits alleging that its products     have resulted or could result in an <font color="blue">unsafe condition</font> or injury to patients</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims and lawsuits and <font color="blue">safety alerts</font> or <font color="blue">product recalls</font>,     <font color="blue">regardless</font> of their ultimate outcome, may have a material adverse effect on     Abbottapstas business and reputation and on Abbottapstas ability to attract and     retain customers</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims could have a material adverse     effect on Abbottapstas <font color="blue">profitability</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Abbott  </font>faces  <font color="blue">significant</font>  <font color="blue">competition</font> and may not be able to compete     <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>Abbott <font color="blue">competes with</font> many companies ranging from other <font color="blue">multinational</font>     companies  to  small start-up companies</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>takes many forms,     including responding to <font color="blue">pricing pressures from managed care groups</font> and     <font color="blue">government</font> agencies, the <font color="blue">development</font> of <font color="blue">new products</font> by <font color="blue">competitors</font> having     <font color="blue">lower prices</font> or superior performance or that are <font color="blue">otherwise <font color="blue">competitive</font> with</font>     Abbottapstas current products, generic <font color="blue">competition</font> when Abbottapstas <font color="blue">products lose</font>     their patent or <font color="blue">regulatory</font> protection, technological advances, patents and     <font color="blue">registrations</font> obtained by <font color="blue">competitors</font>, and business <font color="blue">combination</font>s among     Abbottapstas <font color="blue">competitors</font> or <font color="blue">major customers</font></td>
    </tr>
    <tr>
      <td>Abbottapstas present or <font color="blue">future products</font>     could  be  rendered  obsolete  or  uneconomical  as the result of this     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Abbottapstas failure to compete <font color="blue">effectively</font> could cause it to lose     market share to its <font color="blue">competitors</font> and/or have a material adverse effect on its     revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>External economic forces, over which Abbott has no control, can have a     material adverse effect on Abbottapstas future <font color="blue">profitability</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Many <font color="blue">external economic forces</font> can affect Abbottapstas <font color="blue">profitability</font> and     its <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>For example, to calculate its cost for pension and     post-employment benefits, Abbott must use the long-term <font color="blue">assumptions</font> it has     developed with the assistance of its actuaries</td>
    </tr>
    <tr>
      <td>These include <font color="blue">assumptions</font>     regarding the health care cost trend rate, discount (interest) rate, and the     expected return on plan assets</td>
    </tr>
    <tr>
      <td>Similarly, to determine its stock-based     <font color="blue">compensation</font> costs, Abbott must develop <font color="blue">assumptions</font> regarding the <font color="blue">volatility</font>     of Abbottapstas common shares, option life, the <font color="blue">associated tax benefit</font>, and     discount (interest) rate</td>
    </tr>
    <tr>
      <td>These <font color="blue">assumptions</font> are <font color="blue">based on</font> an analysis of     <font color="blue">external economic factors over which</font> Abbott has no control</td>
    </tr>
    <tr>
      <td>To the extent     these  factors  change  over  time or actual results differ from these     <font color="blue">assumptions</font>,  <font color="blue">Abbott  </font>may  <font color="blue">incur increased costs</font>, some of which may be     material</td>
    </tr>
    <tr>
      <td>not  limited to those identified under “Item 1A Risk Factors” of this     Form 10-K  and  those listed below, may cause actual results to differ     <font color="blue">materially from current <font color="blue">expectation</font>s</font>, estimates, projections, forecasts and     from past results</td>
    </tr>
    <tr>
      <td>•                                          <font color="blue">Competitive </font>factors, including:     (i) pricing pressures, both in <font color="blue">the <font color="blue">United States </font></font>and abroad, primarily from     managed care groups and <font color="blue">government</font> agencies, (ii) the <font color="blue">development</font> of new     products by <font color="blue">competitors</font> having <font color="blue">lower prices</font> or superior performance or that     are <font color="blue">otherwise <font color="blue">competitive</font> with</font> Abbott’s current products, (iii) generic     <font color="blue">competition</font>  when  Abbott’s  products  lose their patent or <font color="blue">regulatory</font>     protection, (iv) technological advances, patents and <font color="blue">registrations</font> obtained     by <font color="blue">competitors</font>, and (v) business <font color="blue">combination</font>s among Abbott’s <font color="blue">competitors</font> or     <font color="blue">major customers</font></td>
    </tr>
    <tr>
      <td>•                                          <font color="blue">Difficulties </font>and delays inherent     in  the  <font color="blue">development</font>,  <font color="blue">manufacturing</font>,  marketing, or sale of products,     including:  (i) <font color="blue">uncertainties</font>  in  the  United  States  Food  and Drug     Administration and foreign <font color="blue"><font color="blue">regulatory</font> approval</font> processes, (ii) delays in the     receipt of or the <font color="blue">inability</font> to obtain required approvals, (iii) efficacy or     safety concerns, (iv) the suspension, revocation, or <font color="blue">adverse amendment</font> of     the  authority  <font color="blue">necessary</font> for <font color="blue">manufacture</font>, marketing, or sale, (v) the     imposition of <font color="blue">additional</font> or <font color="blue">different <font color="blue">regulatory</font></font> <font color="blue">requirements</font>, such as those     <font color="blue"><font color="blue">affecting</font> labeling</font>, (vi) seizure or recall of products, (vii) the failure to     obtain, the imposition of <font color="blue">limitations on</font> the use of, or the loss of patent     and  other  <font color="blue">intellectual</font>  property  rights,  (viii) loss of <font color="blue">regulatory</font>     exclusivity, (ix) <font color="blue">manufacturing</font> or distribution problems, (x) restrictions     on  imports  or  exports,  (xi) problems  with  <font color="blue">licensors</font>,  suppliers,     <font color="blue">distributors</font>, and business partners, and (xii) labor disputes, strikes,     slow-downs or other forms of labor or <font color="blue">union activity</font></td>
    </tr>
    <tr>
      <td>•                                          <font color="blue">Governmental </font>action including:     (i) new laws, <font color="blue">regulations</font> and judicial and <font color="blue">administrative</font> <font color="blue">decisions</font> related     to health care <font color="blue">availability</font>, method of delivery, or the method or amount of     payment or <font color="blue">reimbursement</font> for <font color="blue">health care products</font> and services, (ii) changes     in <font color="blue">the <font color="blue">United States </font></font>Food and Drug Administration and foreign <font color="blue">regulatory</font>     approval processes that may delay or prevent the approval of <font color="blue">new products</font>     and result in lost market <font color="blue">opportunity</font>, (iii) new laws, <font color="blue">regulations</font>, and     judicial and <font color="blue">administrative</font> <font color="blue">decisions</font> <font color="blue">affecting</font> pricing or marketing, and     costs, and (iv) changes in the tax laws, <font color="blue">regulations</font>, and <font color="blue">interpretations</font>     relating to Abbott’s <font color="blue">operations</font>, including laws related to the remittance of     <font color="blue">foreign earnings</font></td>
    </tr>
    <tr>
      <td>•                                          Changes in economic <font color="blue">conditions</font>     over  which  <font color="blue">Abbott  </font>has  no control, including changes in the rate of     inflation, business <font color="blue">conditions</font>, interest rates, foreign currency exchange     rates, market value of Abbott’s <font color="blue">equity <font color="blue">investments</font></font>, and the performance of     <font color="blue">investments</font> held by Abbott’s <font color="blue">employee benefit trusts</font></td>
    </tr>
    <tr>
      <td>______________________________________________________________________         •                                          Changes in business and political     <font color="blue">conditions</font>, including (i) war, political <font color="blue">instability</font>, terrorist attacks in     the  US and other parts of the world, the threat of <font color="blue">future terrorist</font>     activity in the US and other parts of the world and related military     action, (ii) natural <font color="blue">disasters</font>, and (iii) the cost and <font color="blue">availability</font> of     <font color="blue">insurance due</font> to any of the <font color="blue">foregoing events</font></td>
    </tr>
    <tr>
      <td>•                                          Changes in Abbott’s business     units and <font color="blue">investments</font> and changes in the relative and <font color="blue">absolute contribution</font>     of  each  to  earnings  and <font color="blue">cash flow</font> resulting <font color="blue">from evolving</font> business     strategies  and  <font color="blue">opportunities</font>  existing now or in the future, such as     <font color="blue"><font color="blue">acquisition</font>s</font>,  <font color="blue">restructurings</font>,  <font color="blue">dispositions</font>,  spin-offs or split-ups,     including the spin-off of Hospira, Inc</td>
    </tr>
    <tr>
      <td>•                                          Changes in costs or expenses,     including <font color="blue">variations</font> resulting from: (i) changes in product mix and changes     in tax rates both in <font color="blue">the <font color="blue">United States </font></font>and abroad, and (ii) the spin-off of     Hospira, Inc</td>
    </tr>
    <tr>
      <td>•                                          Changes in the <font color="blue">buying patterns</font> of     a major distributor, retailer, or <font color="blue">wholesale customer</font> resulting <font color="blue">from buyer</font>     purchasing <font color="blue">decisions</font>, pricing, seasonality, or other factors</td>
    </tr>
    <tr>
      <td>•                                          Legal <font color="blue">difficulties</font>, any of which     could  preclude  <font color="blue">commercialization</font>  of  products  or  <font color="blue">adversely affect</font>     <font color="blue">profitability</font>,  including:  (i) claims asserting <font color="blue">antitrust violations</font>,     (ii) claims asserting securities law violations, (iii) claims asserting     violations of the Federal False Claims Act, Anti-Kickback Statute, or other     violations  in <font color="blue">connection with</font> Medicare and/or Medicaid <font color="blue">reimbursement</font>,     (iv) claims asserting violations of the Prescription Drug Marketing Act,     (v) derivative actions, (vi) <font color="blue">product <font color="blue">liability</font></font> claims, (vii) disputes over     <font color="blue">intellectual</font> property rights (including patents), (viii) environmental     matters, (ix) adverse <font color="blue">litigation</font> <font color="blue">decisions</font>, (x) issues regarding compliance     with any <font color="blue">government</font>al <font color="blue">consent decree</font>, including the <font color="blue">consent decree</font> between     Abbott and <font color="blue">the <font color="blue">United States </font></font>Food and Drug Administration described in     Abbott’s 2005 Form 10-K under the caption “Regulation,” and Abbott’s ability     to <font color="blue">successfully</font> return diagnostic products <font color="blue">affected by</font> this <font color="blue">consent decree</font>     to market, and (xi) issues regarding <font color="blue">compliance with</font> any <font color="blue">corporate integrity</font>     <font color="blue">agreements</font> which generally impose certain training, auditing, and reporting     <font color="blue">obligations</font> on a company</td>
    </tr>
    <tr>
      <td>•                                          Changes in <font color="blue">accounting</font> standards     and  <font color="blue">interpretations</font>  thereof  promulgated by the Financial Accounting     Standards Board, the Securities and Exchange Commission or the American     Institute of Certified Public Accountants</td>
    </tr>
    <tr>
      <td>No  assurance can be made that any <font color="blue">expectation</font>, estimate or projection     contained in a forward-looking statement will be achieved or will not be     <font color="blue">affected by</font> the <font color="blue">factors cited</font> above or other <font color="blue">future events</font></td>
    </tr>
    <tr>
      <td>Readers are     cautioned not to place undue reliance on such statements, which speak only     as of the date made</td>
    </tr>
    <tr>
      <td>Abbott undertakes <font color="blue">no obligation</font> to <font color="blue">release publicly</font> any     revisions to forward-looking statements as the result of <font color="blue">subsequent events</font>     or <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>______________________________________________________________________       <font color="blue">GRAPHIC    </font>16    g398140</td>
    </tr>
  </tbody>
</table>